Home / Sweden / Xvivo Perfusion Aktiebolag
Xvivo Perfusion Aktiebolag
Short position disclosed on August 31, 2026.
5.01% of the capital sold short
5 disclosing funds
163 disclosures on record
SE0004840718 ISIN code
Evolution of the disclosed total
0%2%4%6%8%
Oct 2025Jan 2026Apr 2026Jul 2026
August 3, 2022 today
Open positions
| Fund | Twelve months | % of capital | Over the year | Since |
|---|---|---|---|---|
| Marchant MC Ltd | 1.57% | +0.12 pt | May 8, 2026 | |
| JPMorgan Asset Management (UK) Ltd | 1.36% | +0.04 pt | July 16, 2026 | |
| Citadel Advisors LLC | 0.89% | -0.25 pt | August 12, 2026 | |
| ActusRayPartners Limited | 0.60% | new | August 31, 2026 | |
| D E Shaw Co LP | 0.59% | unchanged | April 21, 2026 |
On the other side: the funds that hold Xvivo Perfusion Aktiebolag Titelia
Get the moves on Xvivo Perfusion Aktiebolag by mail.
No account: one address, one link to confirm, one link to stop in every message.
History of disclosures
Download 163 filings as CSV Columns: Date, Fund, Market, Disclosed position, Unit, End date. The other formats
Other companies sold short in Sweden
- Samhällsbyggnadsbolaget i Norden AB 12.02% of the capital sold short
- Elekta AB (publ) 9.04% of the capital sold short
- JM AB 7.52% of the capital sold short
- Bonesupport Holding AB 6.56% of the capital sold short
- Hemnet Group AB (publ) 6.00% of the capital sold short
- Truecaller AB 5.98% of the capital sold short
- RaySearch Laboratories AB (publ) 4.78% of the capital sold short
- AAK AB (publ) 4.23% of the capital sold short
- Aktiebolaget Electrolux 4.15% of the capital sold short
- Dynavox Group AB 3.98% of the capital sold short
- Smart Eye Aktiebolag (publ) 3.69% of the capital sold short
- Embracer Group AB 3.64% of the capital sold short
Cite this page
The figure comes from the regulator register, not from this site. Quoting both lets your reader check it.
QuiVad, Xvivo Perfusion Aktiebolag, source Finansinspektionen, data as at August 31, 2026, https://www.quivad.com/action/xvivo-perfusion-aktiebolag